We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 16, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
COMBINATION THERAPY USING ANTI - CD20 ANTIBODY AND HUMAN IL-15
Transport container for animals with fur
COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE
MOULD WITH ROUGHNESS AT THE WELDLINEWALL
HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS